Back to Search
Start Over
Real World Use of the Pediatric Disease Risk Index for Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: A Multicenter Study
- Source :
- Transplantation and Cellular Therapy; February 2024, Vol. 30 Issue: 2, Number 2 Supplement 1 pS107-S108, 2p
- Publication Year :
- 2024
-
Abstract
- To determine the risk of relapse of hematologic malignancies after allogeneic hematopoietic cell transplantation (allo-HCT), a disease risk index (DRI) tool has been used extensively for adult patients. In 2021 a validated DRI, considering age and disease status, for pediatric patients was developed by Qayed et al. (Blood, 2021, 137[7]).
Details
- Language :
- English
- ISSN :
- 26666375 and 26666367
- Volume :
- 30
- Issue :
- 2, Number 2 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Transplantation and Cellular Therapy
- Publication Type :
- Periodical
- Accession number :
- ejs65462669
- Full Text :
- https://doi.org/10.1016/j.jtct.2023.12.171